Verastem RAMPS Up In Rare Ovarian Cancer With Avutometinib/Defactinib Filing
Data Announced In Pancreatic Cancer
The company announced topline data from the RAMP 201 trial in low-grade serous ovarian cancer, a rare disease with no FDA-approved treatments, and started a rolling FDA submission.
